CARLSBAD, Calif., Oct. 9 /PRNewswire-FirstCall/ -- Isis
Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced that it has received a
$1.25 million milestone payment in the form of equity securities in iCo
Therapeutics. The milestone was related to the initiation of Phase 1
clinical trials of iCo-007, a drug licensed to iCo by Isis in 2005 for the
treatment of various eye diseases, including diabetic macular edema.

"Because our antisense technology enables us to rapidly discover so
many highly selective antisense drugs to diverse and important disease
targets, we are not able to invest in the development of every promising
drug candidate. By licensing drugs at various points in development, we can
continue to expand the scope and value of our external pipeline in
therapeutic areas that are outside of our key focus, as evidenced by this
latest clinical milestone from iCo," said C. Frank Bennett, Ph.D., Senior
Vice President of Research at Isis Pharmaceuticals, Inc. "We are
enthusiastic about the potential for iCo-007 as a treatment for diabetic
macular edema."

About iCo-007

Designed and discovered by Isis, iCo-007 is a second-generation
antisense drug that inhibits the production of c-Raf kinase, an enzyme
associated with the formation of new and often abnormal or fragile blood
vessels in the eye. Blood vessel breakage and leakage can contribute to
vision loss, and iCo-007 is expected to decrease swelling in the retina and
related visual impairment by decreasing the signaling of various growth
factors such as VEGF that signal through the c-Raf kinase / MAP kinase
pathway.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel
drugs for its prod'/>"/>

(Date:7/31/2015)... , ... July 31, 2015 , ... ... new store run by GoodThreads. The store can be accessed by visiting ... many of which are customizable. The best part: whenever a product is purchased, ...

(Date:7/31/2015)... ... July 31, 2015 , ... There’s no better way to enjoy ... comes time to cook the next meal, making July the most appropriate to be ... grilling tips and recipes. , Make the next cookout different than the ones in ...

(Date:7/31/2015)... ... July 31, 2015 , ... Coco Libre announced today that their ... VIPs at the 2015 Vans US Open of Surfing, July 25 through August 2 ... “no added sugar” on the market, is a natural choice given the Open’s commitment ...

(Date:7/31/2015)... CA (PRWEB) , ... July 31, 2015 , ... According to the article ... floor of the Pasadena courthouse was contained and extinguished by the city’s fire department before ... in the building at the time of the fire, and it was a fire alarm ...

(Date:7/31/2015)... New York (PRWEB) , ... ... ... trial attorney Jason T. Brown’s live lecture on pharmaceutical negligence is now ... 28th, 2015 was well received with a 94% approval rating from the ...

... PLYMOUTH MEETING, Pa., March 16 /PRNewswire-Asia-FirstCall/ -- BMP,Sunstone Corporation ... the "Company"),today announced that the Company is calling its ... 2009 (the "Original Notes"). In addition, the,Company announced ... -- Exchanged $1.0 million in principal amount ...

... The American Heart Association has announced its national officers ... Neil M. Meltzer, president and chief operating officer of ... LifeBridge Health, also in Baltimore, is chairman. Meltzer will ... and fund raising, and will preside over all Board ...

... fatter, and that obesity has become an epidemic. But there ... Houston sociologist. , While she acknowledges that there has been ... professor Samantha Kwan looks at obesity from a different perspective. ... community, Kwan says. And the use of the Body Mass ...

(Date:7/30/2015)... 30, 2015 Growth of the U.S. nonprescription market ... former prescription users to the OTC market. Due to ... robust Rx-to-OTC switch activity over the next five years ... many new brands entering the market into existing categories. ... five years (even those with low to moderate likelihood), ...

... Oct. 27 Pharmos Corporation (Pink Sheets: PARS ... nine-month period ended September 30, 2010. These results are included ... been filed with the SEC. During the quarter ... potential partners for Dextofisopam, its drug for irritable bowel syndrome ...